News & Events
Read more The Translational Readout #3 - New Publication: Ex Vivo Micro-Tumor Responses Reflect Chemotherapy Outcomes in Bladder Cancer
21 October 2026
Treatment decisions are often made without a reliable way to predict an individual tumorโs response. In our new publication of a study with Erasmus MC and four other Dutch hospitals, we show that fresh tumor tissue can be tested ex vivo to predict clinical treatment responses.
Read more
Read more The Translational Readout #2 - Tumor Heterogeneity: Why Treatment Responses Differ
8 September 2026
Tumors of the same diagnosis can differ substantially in their biology. The same treatment may therefore work differently between patients โ and even across cells within a single tumor.
Read more
Read more ๐ ๐ญ๐ฌ ๐ฌ๐ฒ๐ฎ๐ฟ๐ ๐ผ๐ณ ๐ฉ๐ถ๐๐ฟ๐ผ๐ฆ๐ฐ๐ฎ๐ป!
3 September 2026
Today we celebrate an exciting milestone: 10 years of VitroScan! Over the past decade, we have grown, learned, innovated, and taken important steps towards our mission of supporting better informed treatment decisions for cancer patients through ex vivo micro-tumor testing.
Read moreInfo Sheets
Read more Info Sheet ADC efficacy assessment
1 June 2026
Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform
Read more
Read more Info Sheet Bispecific antibody testing
1 June 2026
Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform
Read more
Read more Our latest publication at a glance!
1 June 2026
Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform
Read moreScientific Posters
Read more VitroScan at AACR 2026
8 April 2026
Download our poster: Ex vivo micro-tumor testing platform to characterize and predict patient-specific immunotherapy responses
Read more
Read more VitroScan at SITC 2025
5 November 2025
Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab
Read more
Read more VitroScan at ENA 2025
22 October 2025
Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer
Read moreScientific Publications
Read more Scholtes et al., European Urology Open Science, 2026
21 October 2026
Publication of our study showing that among bladder cancer patients with available clinical outcomes after platinum-based chemotherapy, ex vivo chemosensitivity scores significantly distinguished responders from non-responders.
Read more
Read more Koedoot et al., npj Precision Oncology, 2025
30 August 2025
Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.
Read more